Definium Therapeutics reported additional Phase 3 progress for its oral LSD candidate DT120 as the company moves toward an FDA submission. In one late-stage readout, DT120 showed an anxiety reduction signal in a large trial, with Definium reporting a 9.8-point drop on the Hamilton Anxiety Rating Scale at a 100-microgram dose versus 4.7 points on placebo. Separately, Definium described another Phase 3 win earlier in the series, reinforcing a pattern of recurring efficacy signals across multiple pivotal readouts. The updates continue to position psychedelic therapy as a leading contender for earlier regulatory consideration in anxiety disorders, dependent on totality of evidence and manufacturing readiness.